{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T09:20:10Z","timestamp":1777454410338,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>Remitting seronegative symmetrical synovitis with pitting edema (RS<jats:sub>3<\/jats:sub>PE) is a rare inflammatory arthritis, with a higher incidence of malignancy. The aim of this study is to identify biomarkers for predicting malignancy in RS<jats:sub>3<\/jats:sub>PE.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 51 patients with RS<jats:sub>3<\/jats:sub>PE from September 2007 to May 2019 were retrospectively reviewed and followed for up to 5 years, with 15 patients with osteoarthritis (OA) and 14 patients with elderly-onset rheumatoid arthritis (EORA) as disease controls. Serum levels of angiogenesis cytokines were measured by electrochemiluminescent immunoassay and Luminex Human Magnetic Assay. Clinical data and laboratory parameters were analyzed to identify risk factors for malignancy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of forty-eight RS<jats:sub>3<\/jats:sub>PE patients (94.1%) were available with follow-up data; 8 patients (16.7%) were diagnosed with malignancy, of which 6 patients were hematological tumor; and 2 patients were solid tumors. Serum levels of basic fibroblast growth factor (bFGF) were exclusively higher in RS<jats:sub>3<\/jats:sub>PE patients with malignancy [14.21 (7.52, 23.18) ng\/mL] than RS<jats:sub>3<\/jats:sub>PE patients without malignancy [4.32 (2.88, 7.42) ng\/mL], OA [3.20 (2.20, 5.30) ng\/mL], and EORA [3.20 (2.20, 5.30) ng\/mL]. The optimal cut-off value of bFGF for malignancy was 10ng\/mL in RS<jats:sub>3<\/jats:sub>PE. Logistic regression analysis indicated that elevation of bFGF was a risk factor for malignancy in RS<jats:sub>3<\/jats:sub>PE.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study indicated that bFGF was elevated in RS<jats:sub>3<\/jats:sub>PE patients with malignancy and could serve as a biomarker for predicting paraneoplastic RS<jats:sub>3<\/jats:sub>PE.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-021-02638-0","type":"journal-article","created":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T20:10:10Z","timestamp":1634328610000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["bFGF could be a biomarker of malignancy in RS3PE syndrome: an ambispective single-center cohort analysis of 51 patients"],"prefix":"10.1186","volume":"23","author":[{"given":"Yuzhou","family":"Gan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiali","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukchiu","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,15]]},"reference":[{"issue":"11","key":"2638_CR1","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/nrrheum.2014.138","volume":"10","author":"B Manger","year":"2014","unstructured":"Manger B, Schett G. Paraneoplastic syndromes in rheumatology. Nat Rev Rheumatol. 2014;10(11):662\u201370.","journal-title":"Nat Rev Rheumatol."},{"issue":"8","key":"2638_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11926-015-0525-0","volume":"17","author":"H Li","year":"2015","unstructured":"Li H, Altman RD, Yao Q. RS3PE: clinical and research development. Curr Rheumatol Rep. 2015;17(8):49.","journal-title":"Curr Rheumatol Rep."},{"issue":"3","key":"2638_CR3","first-page":"404","volume":"34","author":"P Karmacharya","year":"2016","unstructured":"Karmacharya P, Donato AA, Aryal MR, et al. RS3PE revisited: a systematic review and meta-analysis of 331 cases. Clin Exp Rheumatol. 2016;34(3):404\u201315.","journal-title":"Clin Exp Rheumatol."},{"issue":"9","key":"2638_CR4","first-page":"1760","volume":"32","author":"EB Russell","year":"2005","unstructured":"Russell EB. Remitting seronegative symmetrical synovitis with pitting edema syndrome: followup for neoplasia. J Rheumatol. 2005;32(9):1760\u20131.","journal-title":"J Rheumatol."},{"issue":"8","key":"2638_CR5","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.2169\/internalmedicine.4239-19","volume":"59","author":"T Kenzaka","year":"2020","unstructured":"Kenzaka T. The Relationship between remitting seronegative symmetrical synovitis with pitting edema and vascular endothelial growth factor and matrix metalloproteinase 3. Intern Med. 2020;59(8):1021\u20132.","journal-title":"Intern Med."},{"issue":"2","key":"2638_CR6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3109\/14397595.2013.857836","volume":"26","author":"T Tabeya","year":"2016","unstructured":"Tabeya T, Sugaya T, Suzuki C, et al. A case of angioimmunoblastic T-cell lymphoma with high serum VEGF preceded by RS3PE syndrome. Mod Rheumatol. 2016;26(2):281\u20135.","journal-title":"Mod Rheumatol."},{"issue":"11","key":"2638_CR7","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1136\/ard.2004.032995","volume":"64","author":"K Arima","year":"2005","unstructured":"Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis. 2005;64(11):1653\u20135.","journal-title":"Ann Rheum Dis."},{"issue":"5","key":"2638_CR8","doi-asserted-by":"publisher","first-page":"84","DOI":"10.12998\/wjcc.v6.i5.84","volume":"6","author":"T Kenzaka","year":"2018","unstructured":"Kenzaka T, Goda K. Serum matrix metalloproteinase 3 in detecting remitting seronegative symmetrical synovitis with pitting edema syndrome: A case report. World J Clin Cases. 2018;6(5):84\u20137.","journal-title":"World J Clin Cases."},{"issue":"8","key":"2638_CR9","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.2169\/internalmedicine.3713-19","volume":"59","author":"C Hosoda","year":"2020","unstructured":"Hosoda C, Ishiguro T, Morimoto Y, et al. Remitting seronegative symmetrical synovitis with pitting edema syndrome complicated with organizing pneumonia. Intern Med. 2020;59(8):1065\u20139.","journal-title":"Intern Med."},{"issue":"10","key":"2638_CR10","doi-asserted-by":"publisher","first-page":"e389","DOI":"10.1111\/ijd.12854","volume":"54","author":"F Drago","year":"2015","unstructured":"Drago F, Ciccarese G, Agnoletti AF, et al. Remitting seronegative symmetrical synovitis with pitting edema associated with parvovirus B19 infection: two new cases and review of the comorbidities. Int J Dermatol. 2015;54(10):e389\u201393.","journal-title":"Int J Dermatol."},{"issue":"4","key":"2638_CR11","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3109\/s10165-011-0556-y","volume":"22","author":"T Origuchi","year":"2012","unstructured":"Origuchi T, Arima K, Kawashiri SY, et al. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome. Mod Rheumatol. 2012;22(4):584\u20138.","journal-title":"Mod Rheumatol."},{"issue":"5","key":"2638_CR12","doi-asserted-by":"publisher","first-page":"665","DOI":"10.17219\/acem\/94065","volume":"28","author":"T Tuncer","year":"2019","unstructured":"Tuncer T, Kaya A, Gulkesen A, Kal GA, Kaman D, Akgol G. Matrix metalloproteinase-3 levels in relation to disease activity and radiological progression in rheumatoid arthritis. Adv Clin Exp Med. 2019;28(5):665\u201370.","journal-title":"Adv Clin Exp Med."},{"issue":"2","key":"2638_CR13","first-page":"333","volume":"24","author":"A Oliv\u00e9","year":"1997","unstructured":"Oliv\u00e9 A, del Blanco J, Pons M, Vaquero M, Tena X. The clinical spectrum of remitting seronegative symmetrical synovitis with pitting edema. The Catal\u00e1n Group for the Study of RS3PE. J Rheumatol. 1997;24(2):333\u20136.","journal-title":"J Rheumatol."},{"issue":"5","key":"2638_CR14","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.jbspin.2003.07.005","volume":"71","author":"O Gisserot","year":"2004","unstructured":"Gisserot O, Cr\u00e9mades S, Landais C, Leyral G, Bernard P, de Jaur\u00e9guiberry JP. RS3PE revealing recurrent non-Hodgkin\u2019s lymphoma. Joint Bone Spine. 2004;71(5):424\u20136.","journal-title":"Joint Bone Spine."},{"issue":"4","key":"2638_CR15","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s00296-003-0395-z","volume":"24","author":"SE Tunc","year":"2004","unstructured":"Tunc SE, Arslan C, Ayvacioglu NB, Sahin M, Akkus S, Yorgancigil H. Paraneoplastic remitting seronegative symmetrical synovitis with pitting edema (RS3PE syndrome): a report of two cases and review of the literature. Rheumatol Int. 2004;24(4):234\u20137.","journal-title":"Rheumatol Int."},{"issue":"8","key":"2638_CR16","first-page":"1613","volume":"32","author":"N Chiappetta","year":"2005","unstructured":"Chiappetta N, Gruber B. Remitting seronegative symmetrical synovitis with pitting edema associated with acute myeloid leukemia. J Rheumatol. 2005;32(8):1613\u20134.","journal-title":"J Rheumatol."},{"issue":"1","key":"2638_CR17","first-page":"115","volume":"26","author":"J Sibilia","year":"1999","unstructured":"Sibilia J, Friess S, Schaeverbeke T, et al. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE): a form of paraneoplastic polyarthritis. J Rheumatol. 1999;26(1):115\u201320.","journal-title":"J Rheumatol."},{"issue":"2","key":"2638_CR18","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/PL00011218","volume":"21","author":"S Paira","year":"2002","unstructured":"Paira S, Graf C, Roverano S, Rossini J. Remitting seronegative symmetrical synovitis with pitting oedema: a study of 12 cases. Clin Rheumatol. 2002;21(2):146\u20139.","journal-title":"Clin Rheumatol."},{"issue":"1","key":"2638_CR19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1136\/jim-2020-001613","volume":"69","author":"M Lakhmalla","year":"2021","unstructured":"Lakhmalla M, Dahiya DS, Kichloo A, Fatima T, Edigin E, Wani F. Remitting seronegative symmetrical synovitis with pitting edema: a review. J Investig Med. 2021;69(1):86\u201390.","journal-title":"J Investig Med."},{"issue":"21","key":"2638_CR20","doi-asserted-by":"publisher","first-page":"jcs250449","DOI":"10.1242\/jcs.250449","volume":"133","author":"MT Pallotta","year":"2020","unstructured":"Pallotta MT, Nickel W. FGF2 and IL-1\u03b2 - explorers of unconventional secretory pathways at a glance. J Cell Sci. 2020;133(21):jcs250449.","journal-title":"J Cell Sci"},{"issue":"7","key":"2638_CR21","doi-asserted-by":"publisher","first-page":"R255","DOI":"10.1530\/ERC-19-0472","volume":"27","author":"E Labanca","year":"2020","unstructured":"Labanca E, Vazquez ES, Corn PG, et al. Fibroblast growth factors signaling in bone metastasis. Endocr Relat Cancer. 2020;27(7):R255\u201365.","journal-title":"Endocr Relat Cancer."},{"issue":"6","key":"2638_CR22","doi-asserted-by":"publisher","first-page":"a015958","DOI":"10.1101\/cshperspect.a015958","volume":"5","author":"AA Belov","year":"2013","unstructured":"Belov AA, Mohammadi M. Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology. Cold Spring Harb Perspect Biol. 2013;5(6):a015958.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1","key":"2638_CR23","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1080\/16078454.2020.1766865","volume":"25","author":"MZ Song","year":"2020","unstructured":"Song MZ, Mao YM, Wu J, Pan HF, Ye QL. Increased circulating basic fibroblast growth factor levels in acute myeloid leukemia: a meta-analysis. Hematology. 2020;25(1):186\u201393.","journal-title":"Hematology."},{"issue":"3-4","key":"2638_CR24","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.cytogfr.2007.04.011","volume":"18","author":"D Ribatti","year":"2007","unstructured":"Ribatti D, Vacca A, Rusnati M, Presta M. The discovery of basic fibroblast growth factor\/fibroblast growth factor-2 and its role in haematological malignancies. Cytokine Growth Factor Rev. 2007;18(3-4):327\u201334.","journal-title":"Cytokine Growth Factor Rev."},{"issue":"28","key":"2638_CR25","doi-asserted-by":"publisher","first-page":"44735","DOI":"10.18632\/oncotarget.8203","volume":"7","author":"MR Akl","year":"2016","unstructured":"Akl MR, Nagpal P, Ayoub NM, et al. Molecular and clinical significance of fibroblast growth factor 2 (FGF2 \/bFGF) in malignancies of solid and hematological cancers for personalized therapies. Oncotarget. 2016;7(28):44735\u201362.","journal-title":"Oncotarget."},{"issue":"2","key":"2638_CR26","doi-asserted-by":"publisher","first-page":"e9081","DOI":"10.15252\/emmm.201809081","volume":"11","author":"V Chua","year":"2019","unstructured":"Chua V, Orloff M, Teh JL, et al. Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma. EMBO Mol Med. 2019;11(2):e9081.","journal-title":"EMBO Mol Med"},{"issue":"8","key":"2638_CR27","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1002\/art.20367","volume":"50","author":"K Nakano","year":"2004","unstructured":"Nakano K, Okada Y, Saito K, Tanaka Y. Induction of RANKL expression and osteoclast maturation by the binding of fibroblast growth factor 2 to heparan sulfate proteoglycan on rheumatoid synovial fibroblasts. Arthritis Rheum. 2004;50(8):2450\u20138.","journal-title":"Arthritis Rheum."},{"issue":"4","key":"2638_CR28","doi-asserted-by":"publisher","first-page":"R130","DOI":"10.1186\/ar3441","volume":"13","author":"D Yan","year":"2011","unstructured":"Yan D, Chen D, Cool SM, et al. Fibroblast growth factor receptor 1 is principally responsible for fibroblast growth factor 2-induced catabolic activities in human articular chondrocytes. Arthritis Res Ther. 2011;13(4):R130.","journal-title":"Arthritis Res Ther."},{"key":"2638_CR29","doi-asserted-by":"publisher","first-page":"110628","DOI":"10.1016\/j.biopha.2020.110628","volume":"131","author":"S Zhao","year":"2020","unstructured":"Zhao S, Wang Y, Hou L, Wang Y, Xu N, Zhang N. Pentraxin 3 inhibits fibroblast growth factor 2 induced osteoclastogenesis in rheumatoid arthritis. Biomed Pharmacother. 2020;131:110628.","journal-title":"Biomed Pharmacother."},{"issue":"1","key":"2638_CR30","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s13075-016-1184-x","volume":"18","author":"P Smets","year":"2016","unstructured":"Smets P, Devauchelle-Pensec V, Rouzaire PO, Pereira B, Andre M, Soubrier M. Vascular endothelial growth factor levels and rheumatic diseases of the elderly. Arthritis Res Ther. 2016;18(1):283.","journal-title":"Arthritis Res Ther."}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02638-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-021-02638-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02638-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T20:16:18Z","timestamp":1634328978000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-021-02638-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,15]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2638"],"URL":"https:\/\/doi.org\/10.1186\/s13075-021-02638-0","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,15]]},"assertion":[{"value":"14 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethics committee of Peking University People\u2019s Hospital (2020PHB060) and the study complied with the Declaration of Helsinki guidelines. All the participants were given written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"261"}}